Neurology, Neuropsychiatry, Psychosomatics

Advanced search


Full Text:


Seventy patients (40 females and 30 males; mean age 46,5±15,0 years) with acute nonspecific back pain at various sites were followed up in the outpatient setting to study the efficiency of drug therapy based on meloxicam (movalis), without using physiotherapy, acupuncture and manual therapy techniques. The patients took movalis in a dose of 15 mg/day orally or 15 mg/day intramuscularly for up to 5 days, then 15 mg/day orally. Most patients (n = 56) also received myorelaxants (predominantly midocalm). As a result of therapy, back pain completely disappeared or was reduced (from 7,8±1,4 to 1,14± 0,95 visual analogue scores), the routine activity reached the baseline level as had been before pain occurrence; the duration of the disease being less than 2 weeks (mean 11 days). Adverse reactions caused by therapy were observed in sporadic cases; these were mild and transient. Case histories of 2 patients in whom movalis therapy was effective when the use of other nonsteroidal anti-inflammatory drugs failed are presented.

About the Authors

O. N. Gerasimova
ZAO «Medical Services», Polyclinics Two and Six, Moscow West Administrative District
Russian Federation

V. A. Parfenov
I.M. Sechenov Moscow Medical Academy
Russian Federation


1. <div><p>Богачева Л.А., Снеткова Е.П. Боль в спине: клиника, патогенез, принципы ведения (опыт работы амбулаторного отделения боли в спине). Боль 2005;(4):26-30.</p><p>Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно. М., 2005;2:306-31.</p><p>Bogduk N., McGuirk B. Medical management of acute and chronic low back pain. Amsterdam: Elsevier, 2002.</p><p>Burton A.K., Balague F., Cardon G. et al. for the COST B13 working group on european guidelines for prevention in low back pain. How to prevent low back pain. Best Pract Res Clin Rheumatol 2005;19:541-55.</p><p>Van Tulder M., Becker A., Bekkering T. et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006;15(Suppl. 2):169-91.</p><p>Russo R.B. Diagnosis of low back pain: role of imaging studies. Clin Occup Environ Med 2006;5:571-89.</p><p>Chou R., Huffman L.H. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:492-504.</p><p>Shen F.H., Samartzis D., Andersson G.B. Nonsurgical management of acute and chronic low back pain. J Am Acad Orthop Surg 2006;8:477-87.</p><p>Dugan S.A. The role of exercise in the prevention and management of acute low back pain. Clin Occup Environ Med 2006;5:615-632.</p><p>Hayden J.A., van Tulder M.W., Malmivaara A., Koes B.W. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005;(3):CD000335.</p><p>Насонова В.А. Мелоксикам (мовалис) - селективный ингибитор ЦОГ-2 в клинической практике. Науч-практ. ревматол. 2000;(4):16-21.</p><p>Degner F., Lanes S., van Ryn J., Sigmund R. Pharmacological and clinical profile meloхicam. Therapeutic roles of selective COX-2 inhibitors. Eds J.R. Vane, R.M. Botting., London: William Harvey Press, 2001.</p><p>Singh G., Lanes S., Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004;117:100-6.</p><p>Мазуров В.И. Применение мелоксикама (Мовалиса) у больных с ревматическими заболеваниями с сопутствующей ишемической болезнью сердца. Клин. мед. 2004;(12):54-9.</p><p>Алексеев В.В. Применение мелоксикама в лечении люмбоишиалгического синдрома. РМЖ 2003;11(7):416-8.</p><p>Гузева В.И., Гайгалас Л.М., Разумовский М.А. Мовалис в лечении острых дорсопатий. Журн. неврол. и психиатр. 2004;(5):58-9.</p><p>Филатова Е.Г., Кондриков А.В., Истомина О.И. Эффективность и переносимость лечения боли в нижней части спины с использованием инъекционной и таблетированной форм Мовалиса (мелоксикама). Фарматека 2008;(3):23-5.</p><p>Шостак Н.А., Аксенова А.В., Шеметов Д.А. и др. Опыт применения Мовалиса при синдроме болей в нижней части спины (LBP). Тер арх 1999;(11):50-2.</p><p>Colberg K., Hettich M., Sigmund R. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin 1996;13:363-77.</p><p>Del Tacca M., Colucci R., Fornai M. et al. Efficacy and tolerability of meloxicam, COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Ivest 2002;22(12):799-818.</p><p>Dreiser R.L., Parc J.M., Velicitat P., Leu P.L. Oral meloxicam is effective in acute sciatica: two randomized, double-blind trials versus placebo or diclofenac. Inflammation Res 2001; 50(Suppl. 1):17-23.</p><p>Hawkey C., Kahan A., Stenbruck K. et al. Gastrointestinal tolerability of meloxicam com- pared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Rheumatology (Oxford) 1999;38:793-8.</p></div><br />

For citation:

Gerasimova O.N., Parfenov V.A. TREATMENT FOR ACUTE NONSPECIFIC BACK PAIN IN OUTPATIENT PRACTICE. Neurology, Neuropsychiatry, Psychosomatics. 2009;1(3-4):41-46. (In Russ.)

Views: 412

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)